Related coverage linked through entity extraction aliases.
Apr 30, 2026
AbbVie posted record full-year 2025 revenue of $61.2B and raised its 2026 outlook after strong Q1 Skyrizi and Rinvoq sales. Phase 3 AFFIRM data and new FDA submissions highlight pipeline progress, while full-year revenue guidance was lifted to $67.3B.
Jul 22, 2026
Recent Rethinking Clinical Trials Grand Rounds sessions covered the COMPARE-Pediatric IBD study, a hypertension self-management texting intervention for Black Veterans, and the upcoming Pediatric Trials Network presentation.
Jun 23, 2026
Duvakitug showed durable clinical and endoscopic efficacy over 44 weeks in UC and Crohn's patients in a phase 2b LTE study. The results reinforce duvakitug's potential as a best-in-class TL1A therapy. Both doses were well tolerated.
May 28, 2026
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
Jul 09, 2026
Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Jul 24, 2026
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Jul 31, 2026
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
Jun 25, 2026
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Jun 13, 2026
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
Apr 28, 2026
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Apr 26, 2026
Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
Apr 23, 2026
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
Apr 23, 2026
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Apr 19, 2026
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Apr 17, 2026
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Apr 04, 2026
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
Mar 21, 2026
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Mar 19, 2026
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
Mar 18, 2026
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Mar 16, 2026
Three recent studies reveal connections between gut microbiome composition and health outcomes, identifying specific bacterial groups associated with recovery and disease, plus genetic variants that shape microbial communities.
